Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
ABT Quote, Financials, Valuation and Earnings
Last price:
$108.48
Seasonality move
:
3.19%
Day range:
$108.96 - $110.75
52-week range:
$105.27 - $139.06
Dividend yield:
2.22%
P/E ratio:
29.09x
P/S ratio:
4.27x
P/B ratio:
3.60x
Volume:
10.8M
Avg. volume:
10.2M
1-year change:
-16.89%
Market cap:
$187.9B
Revenue:
$44.3B
EPS (TTM):
$3.72
Analysts' Opinion
-
Consensus RatingAbbott Laboratories has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $132.64, Abbott Laboratories has an estimated upside of 22.66% from its current price of $110.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $113.00 representing -4.49% downside risk from its current price of $110.25.
Fair Value
-
According to the consensus of 23 analysts, Abbott Laboratories has 22.66% upside to fair value with a price target of $132.64 per share.
ABT vs. S&P 500
-
Over the past 5 trading days, Abbott Laboratories has underperformed the S&P 500 by -3.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Abbott Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Abbott Laboratories has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Abbott Laboratories reported revenues of $11.5B.
Earnings Growth
-
Abbott Laboratories earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Abbott Laboratories reported earnings per share of $1.03.
Enterprise value:
193.8B
EV / Invested capital:
2.90x
Price / LTM sales:
4.27x
EV / EBIT:
23.36x
EV / Revenue:
4.37x
PEG ratio (5yr expected):
0.10x
EV / Free cash flow:
26.20x
Price / Operating cash flow:
25.57x
Enterprise value / EBITDA:
16.98x
Gross Profit (TTM):
$23.4B
Return On Assets:
7.78%
Net Income Margin (TTM):
14.66%
Return On Equity:
12.91%
Return On Invested Capital:
10.13%
Operating Margin:
20.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $40.1B | $42B | $44.3B | $11B | $11.5B | |
| Gross Profit | $20B | $21.4B | $23.4B | $5.6B | $6.1B | |
| Operating Income | $6.5B | $6.9B | $8.3B | $2B | $2.4B | |
| EBITDA | $9.7B | $10.1B | $11.4B | $2.8B | $3.2B | |
| Diluted EPS | $3.27 | $7.66 | $3.72 | $5.29 | $1.03 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24.2B | $25.2B | $22.7B | $23.7B | $26B | |
| Total Assets | $75.2B | $74.4B | $73.2B | $81.4B | $86.7B | |
| Current Liabilities | $13.1B | $15.5B | $13.8B | $14.2B | $16.5B | |
| Total Liabilities | $39.2B | $37.5B | $34.4B | $33.5B | $33.9B | |
| Total Equity | $36B | $36.9B | $38.8B | $47.9B | $52.8B | |
| Total Debt | $19B | $17.7B | $15.6B | $15B | $13.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $7.3B | $8.6B | $9.6B | $2.9B | $3.3B | |
| Cash From Investing | -$3.1B | -$2.3B | -$2.4B | -$866M | -$913M | |
| Cash From Financing | -$7.1B | -$5.4B | -$6.3B | -$1.9B | -$1.4B | |
| Free Cash Flow | $5.1B | $6.4B | $7.4B | $2.1B | $2.6B | |
ABT
Sector
Market Cap
$187.9B
$25.3M
Price % of 52-Week High
77.77%
48.74%
Dividend Yield
2.22%
0%
Shareholder Yield
2.19%
-1.64%
1-Year Price Total Return
-16.99%
-19.12%
Beta (5-Year)
0.741
0.492
Dividend yield:
2.22%
Annualized payout:
$2.36
Payout ratio:
61.15%
Growth streak:
12 years
Technicals
8-day SMA
Sell
Level
$111.86
200-day SMA
Sell
Level
$126.54
Bollinger Bands (100)
Sell
Level
113.62 - 128.26
Chaikin Money Flow
Buy
Level
2.1B
20-day SMA
Sell
Level
$112.99
Relative Strength Index (RSI14)
Sell
Level
41.53
ADX Line
Sell
Level
18.74
Williams %R
Buy
Level
-99.1995
50-day SMA
Sell
Level
$115.57
MACD (12, 26)
Sell
Level
-0.94
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
2.4B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.6071)
Buy
CA Score
(Annual)
Level (0.6143)
Buy
Beneish M-Score
(Annual)
Level (-2.5103)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.185)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Stock Forecast FAQ
In the current month, ABT has received 16 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ABT average analyst price target in the past 3 months is $132.64.
-
Where Will Abbott Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Abbott Laboratories share price will rise to $132.64 per share over the next 12 months.
-
What Do Analysts Say About Abbott Laboratories?
Analysts are divided on their view about Abbott Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Abbott Laboratories is a Sell and believe this share price will drop from its current level to $113.00.
-
What Is Abbott Laboratories's Price Target?
The price target for Abbott Laboratories over the next 1-year time period is forecast to be $132.64 according to 23 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ABT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Abbott Laboratories is a Buy. 16 of 23 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABT?
You can purchase shares of Abbott Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Abbott Laboratories shares.
-
What Is The Abbott Laboratories Share Price Today?
Abbott Laboratories was last trading at $108.48 per share. This represents the most recent stock quote for Abbott Laboratories. Yesterday, Abbott Laboratories closed at $110.25 per share.
-
How To Buy Abbott Laboratories Stock Online?
In order to purchase Abbott Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ABT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABT
Sector
P/E ratio
29.09x
21.47x
PEG ratio
0.10x
-0.01x
P/B ratio
3.60x
1.74x
Price / LTM sales
4.27x
1.45x
Growth Metrics
ABT
Sector
Revenue growth
4.42%
3.36%
Earnings growth
-80.51%
11.93%
Revenue (5-year growth)
5.08%
6.25%
Earnings forecast
$1.49
-$0.20
Profitability
ABT
Sector
Profitability FY 2025
$23.4B
$2.2M
Return on invested capital
10.13%
-33.31%
Return on assets
7.78%
-29.82%
Return on equity
12.91%
-40.01%
Earnings Date
Last Earnings Date
Jan
22
Next Earnings Date
Apr
15
Estimated Next Earnings Date
Apr
23
Balance Sheet
ABT
Sector
Total cash
$8.9B
$24.9M
Short term investments
$351M
$23.2M
Total assets
$86.7B
$69.8M
Long term debt
$13.9B
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 6.46% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.61% over the past day.
Buy
88
NBTX alert for Mar 13
Nanobiotix SA [NBTX] is down 1.41% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
